ScriptBio AI
ScriptBio AI provides an AI-native drug discovery platform that harmonizes large-scale human single-cell transcriptomic data to map disease-relevant cell states and assess target candidacy through layered causal evidence. The platform uses agentic research workflows to synthesize scientific literature, clinical development, intellectual property, and competitive activity into structured output for transparent target prioritization. The company is initially validating its platform against knee osteoarthritis, a condition with substantial unmet need.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- AI Agents
- Healthcare Technology
- Data & Analytics
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional drug target discovery often relies on animal models or reductionist in vitro systems that fail to capture human disease biology, leading to high failure rates in clinical development. Researchers also struggle to integrate vast, heterogeneous single-cell datasets and synthesize the ever-expanding scientific, clinical, and competitive literature, making unbiased target prioritization slow and opaque.
Solution
ScriptBio AI provides an AI-native discovery platform that harmonizes large-scale human single-cell transcriptomic data to map disease-relevant cell states across studies and patient populations. The platform applies layered causal discovery methods to assess target candidacy, integrating evidence from human data to nominate targets with high translational confidence. Agentic research workflows automatically organize and synthesize evidence from scientific literature, clinical development, intellectual property, and competitive activity, producing structured output that supports transparent target assessment and experimental prioritization. This enables researchers to make clearer, more defensible decisions about which programs to advance. The company is initially validating its platform against knee osteoarthritis, a condition with significant unmet need, and is designed for flexible target-discovery collaborations with pharma and biotech partners.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking data-driven target discovery and validation partnerships, as well as research organizations focused on complex human diseases where single-cell resolution and causal inference are critical.
Features
- Data foundation integrating and harmonizing 500,000+ human single-cell transcriptomic profiles from five distinct studies
- Causal target discovery framework that layers multiple lines of human-derived evidence to evaluate target-disease relationships
- Agentic research workflows that autonomously synthesize scientific literature, clinical development data, intellectual property, and competitive intelligence
- Structured evidence output designed for transparent target assessment and experimental prioritization decisions
- Flexible platform architecture supporting both external target-discovery collaborations and internal advancement of high-confidence programs
- Initial proof-case program focused on knee osteoarthritis to generate reproducible biological validation of computationally nominated targets